Affordable Access

Publisher Website

Use of infliximab in the treatment of Crohn's disease in children and adolescents

Authors
Journal
The Journal of Pediatrics
0022-3476
Publisher
Elsevier
Volume
137
Issue
2
Identifiers
DOI: 10.1067/mpd.2000.107161
Disciplines
  • Medicine

Abstract

Abstract Background: Crohn's disease is often poorly responsive to conventional therapy with corticosteroids and immunomodulators. A novel chimeric antibody to tumor necrosis factor-α, infliximab, has shown utility in the treatment of refractory Crohn's disease in adults. Purpose: To evaluate the efficacy of open-label administration of infliximab in children and adolescents with active intestinal Crohn's disease. Methods: Chart review of the experience with 19 subjects (mean age 14.4 years, range 9 to 19 years) receiving 1 to 3 infusions of infliximab (5 mg/kg/dose) over a 12-week period for corticosteroid-resistant disease (n = 7) or corticosteroid dependence (n = 12). Disease activity was monitored by physician global assessment and the Pediatric Crohn's Disease Activity Index. Results: Significant initial improvement (first 4 weeks after infusion) was noted in all subjects, with Pediatric Crohn's Disease Activity Index values decreasing significantly (mean ± SD, 42.1 ± 13.7 to 10.0 ± 5.6, P < .0001). Over the subsequent 8-week period, 8 of 19 treated subjects had worsening of symptoms, although none deteriorated to severe activity. The mean Pediatric Crohn's Disease Activity Index at 12 weeks was 26.8 ± 16.4. The mean daily prednisone dosages at baseline, 4 weeks, and 12 weeks were 28 ± 14 mg, 20 ± 12 mg, and 8 ± 12 mg, respectively (P < .01). Adverse effects were noted in 3 patients during infusion (dyspnea, rash) and were self-limited. Conclusions: Infliximab is associated with short-term clinical improvement in children and adolescents with severe Crohn's disease. The rapid return of disease activity in some patients suggests that additional dosing strategies may be required. Long-term safety necessitates close monitoring. (J Pediatr 2000;137:192-6)

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Use of infliximab in the treatment of Crohn's dise...

on Journal of Pediatric Gastroent... September 2001

Use of infliximab in the treatment of Crohn's dise...

on The Journal of Pediatrics August 2000

The use of infliximab in South-east Asian children...

on Pediatrics international : off... April 2004

Infliximab use in Crohn's disease.

on Expert Opinion on Biological T... April 2005
More articles like this..